DK3511000T3 - Krystallinsk form x2 af grapiprant - Google Patents

Krystallinsk form x2 af grapiprant Download PDF

Info

Publication number: DK3511000T3
Authority: DK; Denmark
Prior art keywords: grapiprant; crystallinic; crystallinic form
Prior art date: 2014-03-06

Application number

DK19156369.1T

Other languages

English (en)

Inventor

Tamara Newbold

Melissa Smith

Christopher Seekamp

Robert Wenslow

Xia Lu

Original Assignee

Elanco Animal Health Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-06

Filing date

2015-03-05

Publication date

2022-05-30

2015-03-05 Application filed by Elanco Animal Health Incorporated filed Critical Elanco Animal Health Incorporated

2022-05-30 Application granted granted Critical

2022-05-30 Publication of DK3511000T3 publication Critical patent/DK3511000T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Led Devices (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Ceramic Products (AREA)
Inorganic Insulating Materials (AREA)

DK19156369.1T 2014-03-06 2015-03-05 Krystallinsk form x2 af grapiprant DK3511000T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461949006P	2014-03-06	2014-03-06
US201461996961P	2014-07-30	2014-07-30
EP15758500.1A EP3113773B1 (en)	2014-03-06	2015-03-05	Crystalline forms of grapiprant

Publications (1)

Publication Number	Publication Date
DK3511000T3 true DK3511000T3 (da)	2022-05-30

Family

ID=54016295

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK17193737.8T DK3295941T3 (da)	2014-03-06	2015-03-05	Fremgangsmåde til fremstilling af form a af grapiprant
DK19156369.1T DK3511000T3 (da)	2014-03-06	2015-03-05	Krystallinsk form x2 af grapiprant
DK15758500T DK3113773T3 (da)	2014-03-06	2015-03-05	Krystallinske former af grapiprant

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK17193737.8T DK3295941T3 (da)	2014-03-06	2015-03-05	Fremgangsmåde til fremstilling af form a af grapiprant

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK15758500T DK3113773T3 (da)	2014-03-06	2015-03-05	Krystallinske former af grapiprant

Country Status (16)

Country	Link
US (1)	US9265756B2 (da)
EP (4)	EP3113773B1 (da)
JP (2)	JP6535683B2 (da)
KR (2)	KR101697914B1 (da)
CN (11)	CN107501263A (da)
AU (1)	AU2015227064B2 (da)
CA (10)	CA2997703A1 (da)
DK (3)	DK3295941T3 (da)
ES (3)	ES2816057T3 (da)
MX (2)	MX367376B (da)
NZ (3)	NZ733234A (da)
PL (3)	PL3295941T3 (da)
PT (3)	PT3511000T (da)
RU (1)	RU2638931C1 (da)
TW (1)	TWI537270B (da)
WO (1)	WO2015134797A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12109218B2 (en)	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
TWI664969B (zh) *	2014-03-06	2019-07-11	雅瑞塔那醫療公司	格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
CA3096546A1 (en)	2018-04-16	2019-10-24	Arrys Therapeutics, Inc.	Ep4 inhibitors and use thereof
EP3820469A4 (en) *	2018-07-11	2022-04-13	Arrys Therapeutics, Inc.	EP4 INHIBITORS AND SYNTHESIS THEREOF
US20210315909A1 (en)	2018-07-11	2021-10-14	Arrys Therapeutics, Inc.	Polymorphic compounds and uses thereof
US11254675B2 (en) *	2019-08-12	2022-02-22	Cadila Healthcare Limited	Process for preparation of grapiprant
WO2021226162A1 (en)	2020-05-05	2021-11-11	Arrys Therapeutics, Inc.	Ep4 antagonists and their use in the treatment of proliferative diseases
CN116283959A (zh) *	2021-12-10	2023-06-23	江苏慧聚药业股份有限公司	格拉匹纶新晶型及其制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2001000224A (es)	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2600510C (en) *	2005-03-11	2010-11-02	Pfizer Inc.	Crystal forms of an imidazole derivative
CN101218228A (zh) *	2005-05-23	2008-07-09	诺瓦提斯公司	4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
SG177203A1 (en) *	2006-12-15	2012-01-30	Glaxo Group Ltd	Benzamide derivatives as ep4 receptor agonists
WO2010019796A1 (en) *	2008-08-14	2010-02-18	Chemietek, Llc	Heterocyclic amide derivatives as ep4 receptor antagonists
MX350024B (es)	2011-05-18	2017-08-23	Raqualia Pharma Inc	Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.

2015
- 2015-03-05 DK DK17193737.8T patent/DK3295941T3/da active
- 2015-03-05 ES ES17193737T patent/ES2816057T3/es active Active
- 2015-03-05 WO PCT/US2015/019043 patent/WO2015134797A1/en not_active Ceased
- 2015-03-05 PT PT191563691T patent/PT3511000T/pt unknown
- 2015-03-05 CN CN201710831795.4A patent/CN107501263A/zh not_active Withdrawn
- 2015-03-05 CA CA2997703A patent/CA2997703A1/en not_active Abandoned
- 2015-03-05 CA CA3105571A patent/CA3105571A1/en active Pending
- 2015-03-05 NZ NZ733234A patent/NZ733234A/en unknown
- 2015-03-05 NZ NZ724923A patent/NZ724923A/en unknown
- 2015-03-05 PT PT157585001T patent/PT3113773T/pt unknown
- 2015-03-05 CN CN201710832497.7A patent/CN107759591A/zh not_active Withdrawn
- 2015-03-05 CA CA2997692A patent/CA2997692A1/en not_active Abandoned
- 2015-03-05 NZ NZ733225A patent/NZ733225A/en unknown
- 2015-03-05 DK DK19156369.1T patent/DK3511000T3/da active
- 2015-03-05 ES ES19156369T patent/ES2919346T3/es active Active
- 2015-03-05 CA CA2997746A patent/CA2997746A1/en not_active Abandoned
- 2015-03-05 CN CN201580002716.8A patent/CN105764508A/zh active Pending
- 2015-03-05 EP EP15758500.1A patent/EP3113773B1/en active Active
- 2015-03-05 PT PT171937378T patent/PT3295941T/pt unknown
- 2015-03-05 CA CA2997718A patent/CA2997718A1/en active Pending
- 2015-03-05 MX MX2016011023A patent/MX367376B/es active IP Right Grant
- 2015-03-05 DK DK15758500T patent/DK3113773T3/da active
- 2015-03-05 KR KR1020167024256A patent/KR101697914B1/ko active Active
- 2015-03-05 CN CN202110197159.7A patent/CN113087705A/zh active Pending
- 2015-03-05 CN CN201710831735.2A patent/CN107400132A/zh not_active Withdrawn
- 2015-03-05 CA CA2997741A patent/CA2997741A1/en not_active Abandoned
- 2015-03-05 CN CN201910653673.XA patent/CN110256426A/zh active Pending
- 2015-03-05 AU AU2015227064A patent/AU2015227064B2/en active Active
- 2015-03-05 ES ES15758500T patent/ES2755396T3/es active Active
- 2015-03-05 CN CN201710831743.7A patent/CN107540671A/zh not_active Withdrawn
- 2015-03-05 PL PL17193737T patent/PL3295941T3/pl unknown
- 2015-03-05 TW TW104107082A patent/TWI537270B/zh active
- 2015-03-05 CA CA2997694A patent/CA2997694C/en active Active
- 2015-03-05 PL PL15758500T patent/PL3113773T3/pl unknown
- 2015-03-05 US US14/639,916 patent/US9265756B2/en active Active
- 2015-03-05 CA CA2941019A patent/CA2941019A1/en not_active Withdrawn
- 2015-03-05 PL PL19156369.1T patent/PL3511000T3/pl unknown
- 2015-03-05 EP EP19156369.1A patent/EP3511000B1/en active Active
- 2015-03-05 EP EP17193737.8A patent/EP3295941B1/en active Active
- 2015-03-05 MX MX2018003837A patent/MX388969B/es unknown
- 2015-03-05 RU RU2016139096A patent/RU2638931C1/ru active
- 2015-03-05 CN CN201710831540.8A patent/CN107501262A/zh active Pending
- 2015-03-05 CN CN201710832196.4A patent/CN107759589A/zh active Pending
- 2015-03-05 CA CA2997697A patent/CA2997697A1/en not_active Abandoned
- 2015-03-05 CA CA3168877A patent/CA3168877A1/en active Pending
- 2015-03-05 EP EP19156370.9A patent/EP3520790A1/en not_active Withdrawn
- 2015-03-05 CN CN201710831494.1A patent/CN107573339A/zh not_active Withdrawn
- 2015-03-05 CN CN201710832416.3A patent/CN107759590A/zh not_active Withdrawn
- 2015-03-05 JP JP2016555827A patent/JP6535683B2/ja active Active
- 2015-03-05 KR KR1020177000896A patent/KR101771385B1/ko active Active
2017
- 2017-11-10 JP JP2017217662A patent/JP2018065819A/ja active Pending

Also Published As

Publication number	Publication date
NZ724923A (en)	2018-03-23
ES2919346T3 (es)	2022-07-26
CN105764508A (zh)	2016-07-13
NZ733234A (en)	2018-08-31
CN107759589A (zh)	2018-03-06
EP3295941B1 (en)	2020-07-22
AU2015227064A1 (en)	2016-10-27
KR20160106779A (ko)	2016-09-12
PT3113773T (pt)	2019-11-12
NZ733225A (en)	2018-03-23
TWI537270B (zh)	2016-06-11
CA2997741A1 (en)	2015-09-11
PT3511000T (pt)	2022-05-25
CN107759591A (zh)	2018-03-06
KR101697914B1 (ko)	2017-01-18
JP2017507161A (ja)	2017-03-16
KR101771385B1 (ko)	2017-08-24
EP3113773B1 (en)	2019-09-18
PL3511000T3 (pl)	2022-08-22
MX2016011023A (es)	2016-11-28
CA2997703A1 (en)	2015-09-11
CA3105571A1 (en)	2015-09-11
PL3113773T3 (pl)	2020-05-18
CA2997694A1 (en)	2015-09-11
DK3113773T3 (da)	2019-11-18
CA2997692A1 (en)	2015-09-11
EP3511000A1 (en)	2019-07-17
EP3295941A1 (en)	2018-03-21
EP3511000B1 (en)	2022-04-27
PL3295941T3 (pl)	2020-11-16
PT3295941T (pt)	2020-08-25
US20150250774A1 (en)	2015-09-10
WO2015134797A1 (en)	2015-09-11
CA2997746A1 (en)	2015-09-11
EP3113773A1 (en)	2017-01-11
US9265756B2 (en)	2016-02-23
CN107501263A (zh)	2017-12-22
JP6535683B2 (ja)	2019-06-26
EP3520790A1 (en)	2019-08-07
MX367376B (es)	2019-08-16
CN110256426A (zh)	2019-09-20
CN107501262A (zh)	2017-12-22
CA2997718A1 (en)	2015-09-11
KR20170008889A (ko)	2017-01-24
RU2638931C1 (ru)	2017-12-19
AU2015227064B2 (en)	2017-05-11
CA2941019A1 (en)	2015-09-11
TW201538500A (zh)	2015-10-16
EP3113773A4 (en)	2017-05-10
JP2018065819A (ja)	2018-04-26
CA2997694C (en)	2021-04-06
CN107540671A (zh)	2018-01-05
CN113087705A (zh)	2021-07-09
CN107573339A (zh)	2018-01-12
ES2755396T3 (es)	2020-04-22
CN107400132A (zh)	2017-11-28
MX388969B (es)	2025-03-20
CN107759590A (zh)	2018-03-06
ES2816057T3 (es)	2021-03-31
CA3168877A1 (en)	2015-09-11
CA2997697A1 (en)	2015-09-11
DK3295941T3 (da)	2020-08-24

Publication	Publication Date	Title
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da)	2019-07-22	Dihydropyrrolopyridininhibitorer af ror-gamma
DK3851537T3 (da)	2024-03-18	Behandling af hyperbilirubinæmi
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3233887T3 (da)	2019-05-13	Immunmodulatorer
DK3180331T3 (da)	2022-09-12	Polymorfer af selinexor
DK3164380T3 (da)	2022-03-28	Hæmmere af lysinspecifik demethylase-1
DK3160956T3 (da)	2020-08-31	Inhibitorer af lysin-specifik demethylase-1
DK3006072T3 (da)	2021-10-25	Karadgang
DK3171891T3 (da)	2025-12-15	Fremgangsmåde
DK3514109T3 (da)	2021-05-25	Hydropyrolyse af biomasseholdige råmaterialer
DK3132009T3 (da)	2023-02-06	Fremgangsmåde
DK3220891T3 (da)	2019-11-04	Sublingual formulering af riluzol
DK3283210T3 (da)	2021-11-22	Fremgangsmåde
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3511000T3 (da)	2022-05-30	Krystallinsk form x2 af grapiprant
DK3204352T3 (da)	2020-09-28	Hæmmere af lysin-gingipain
DK3418273T3 (da)	2022-03-21	Derivater af flavagliner
DK3137449T3 (da)	2020-03-02	Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3201323T3 (da)	2020-02-03	Modificering af bakteriofag
IL254502A0 (en)	2017-11-30	Solid forms of menaquinols
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
DK3212800T3 (da)	2021-12-06	21-hydroxylering af steroider
FR3024647B1 (fr)	2017-02-17	Transat de puericulture